All In Biotech

Drug Trial Radar · NCT02433093

A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)

A Single-Center, Randomized, Investigator/Participant-Blind, Placebo-Controlled, Multiple-Ascending Dose, Semi-Sequential Adaptive Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Basimglurant Following Oral Administration in Healthy Subjects and in Patients With Major Depressive Disorder

Last checked: Nov 19, 2026Latest source record: Nov 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Apr 2015

Primary completion

Sep 2015

Study completion Sep 2015

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 4, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study will assess the safety, tolerability, and pharmacokinetics of basimglurant compared to placebo after multiple ascending oral doses for up to 22 days in healthy subjects and in patients with MDD on stable selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) background therapy.

Conditions

  • Major Depressive Disorder, Healthy Volunteer

Interventions

  • BasimglurantDrug

    Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.

  • PlaceboDrug

    Participants will receive 22 days of once-daily oral matching placebo capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Incidence of adverse events (AEs)Time frame: Up to 10 weeks
  2. Safety: Suicidality as assessed using the Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Up to 10 weeks
  3. Safety: Sleep habits as assessed using a participant-recorded sleep diaryTime frame: Up to 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Garden Grove, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.